Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.

Binliang Liu Zong-Bi YiYanfang GuanQuchang OuyangChunxiao LiXiuwen GuanDan LvLixi LiJingtong ZhaiHaili QianBing-He Xu Zongbi YiYixin Zeng

Published in: Cancer medicine (2022)

TP53 mutation can be used to identify biomarkers of anti-HER2 antibody drug resistance in HER2+ patients and HER2 TKI resistance in HER2-/mut patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
tyrosine kinase
nucleic acid
label free